Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving Take-Two Interactive Software, Inc. and its officers or directors [1]. Group 1: Company Developments - On May 2, 2025, Take-Two's subsidiary Rockstar Games announced a new release date for Grand Theft Auto VI, moving it to May 26, 2026, from a previously projected fall 2025 release [3]. - Following the announcement of the delayed release, Take-Two's stock price dropped by $15.67 per share, or 6.66%, closing at $219.50 per share on the same day [3]. Group 2: Legal Investigation - Pomerantz LLP is actively seeking investors of Take-Two who may have been affected by the alleged securities fraud and unlawful business practices [1]. - The firm has a long history in corporate, securities, and antitrust class litigation, having recovered numerous multimillion-dollar damages awards for victims of securities fraud [4].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Globus Medical, Inc. and its officers or directors [1] Financial Performance - On May 8, 2025, Globus reported non-GAAP earnings per share of $0.68, missing consensus estimates by $0.06 [3] - The company reported revenue of $598.12 million, which was $27.78 million below consensus estimates and represented a 1.4% year-over-year decline [3] - Following the financial results announcement, Globus's stock price fell by $16.64 per share, or 22.96%, closing at $55.82 per share on May 9, 2025 [3] Company Challenges - The decline in financial performance was attributed to softer Enabling Technology deal closures, temporary integration-related supply chain disruptions, and the timing of international distributor orders [3]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Travere Therapeutics, Inc. and its officers or directors [1] Group 1: Company Developments - On May 15, 2025, Travere announced that the FDA plans to hold an advisory committee meeting regarding its supplemental New Drug Application for FILSPARI, aimed at treating focal segmental glomerulosclerosis [3] - Following the FDA announcement, Travere's stock price dropped by $4.35 per share, a decline of 20.57%, closing at $16.80 per share on May 16, 2025 [3] Group 2: Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [4] - The firm has successfully recovered numerous multimillion-dollar damages awards for class members over its 85-year history [4]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Savara Inc. and its officers or directors, following a significant stock price drop after negative FDA news [1][3]. Group 1: Investigation Details - Pomerantz LLP is representing investors of Savara Inc. and is looking into claims of securities fraud or other unlawful business practices [1]. - Investors are encouraged to contact Pomerantz LLP for more information regarding the investigation [1]. Group 2: Stock Performance - On May 27, 2025, Savara announced it received a refusal to file letter from the FDA regarding its Biologics License Application for MOLBREEVI, leading to a stock price decline of $0.90 per share, or 31.69%, closing at $1.94 per share [3].

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit is pending against Rocket Companies, Inc. (“Rocket Companies” or the “Company”) (NYSE: RKT). Investors in Rocket Companies securities are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whet ...

Core Viewpoint - Open Lending Corporation is facing a class action lawsuit due to significant financial losses and misleading statements regarding its business operations and revenue forecasts during the class period from February 24, 2022, to March 31, 2025 [1][5]. Financial Performance - On March 17, 2025, Open Lending announced it would delay its Annual Report for 2024, leading to a share price drop of $0.40, or 9.28%, closing at $3.91 [2]. - The following day, the stock fell further by $0.42, or 10.87%, to close at $3.49 [2]. - On March 31, 2025, the company reported a quarterly revenue of negative $56.9 million, primarily due to an $81.3 million reduction in estimated profit share revenues linked to heightened delinquencies and defaults on loans originated between 2021 and 2024 [3]. - The company also reported a net loss of $144 million, impacted by an $86.1 million valuation allowance on deferred tax assets [3]. Share Price Reaction - Following the financial disclosures on April 1, 2025, Open Lending's share price plummeted by $1.59, or 57.61%, closing at $1.17 [4]. Lawsuit Details - The class action lawsuit alleges that Open Lending made materially false and misleading statements regarding its risk-based pricing models, profit share revenue, and the value of its vintage loans [5]. - Specific allegations include misrepresentation of the capabilities of the company's pricing models and failure to disclose the significant depreciation of its 2021 and 2022 vintage loans [5]. Legal Action - Investors who purchased Open Lending securities during the class period have until June 30, 2025, to file a lead plaintiff motion in the class action lawsuit [1][6].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In DoubleVerify To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $75,000 in DoubleVerify between November 10, 2023 and February 27, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, June 4, 2025 ...

Core Viewpoint - Metallus Inc. is under investigation for potential securities fraud and unlawful business practices following disappointing financial results for Q1 2025, which led to a significant drop in stock price [1][3]. Financial Performance - Metallus reported non-GAAP earnings per share of $0.07 for Q1 2025, missing consensus estimates by $0.05 [3]. - The company's stock price fell by $1.48, or 11.31%, closing at $11.61 per share on May 9, 2025, following the earnings announcement [3]. Company Challenges - The CEO of Metallus indicated that the company experienced volatility in the defense supply chain during Q1 2025, attributed to customer manufacturing start-up challenges [3].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Redwire Corporation and its executives, following disappointing financial results and stock price decline [1][3]. Financial Performance - Redwire reported Q1 2025 revenue of $61.4 million, which was $13.14 million below consensus estimates, marking a 30.1% decline year-over-year [3]. - The company attributed the revenue shortfall to delays in U.S. government contract awards, linked to leadership transitions at agencies such as NASA and the Space Development Agency, as well as changing budget priorities under the Trump administration [3]. Stock Market Reaction - Following the release of the financial results, Redwire's stock price decreased by $0.75, or 6.63%, closing at $10.56 per share on May 12, 2025 [4].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Travere Therapeutics, Inc. and its officers or directors [1] Group 1: Company Developments - On May 15, 2025, Travere announced that the FDA plans to hold an advisory committee meeting regarding its supplemental New Drug Application for FILSPARI, aimed at treating focal segmental glomerulosclerosis [3] - Following this announcement, Travere's stock price dropped by $4.35, or 20.57%, closing at $16.80 per share on May 16, 2025 [3] Group 2: Legal Investigation - Pomerantz LLP is reaching out to investors of Travere for claims related to potential securities fraud [1] - The firm is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud [4]